Timing of hypertonic saline inhalation for cystic fibrosis

被引:12
|
作者
Elkins, Mark [1 ]
Dentice, Ruth [2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Edward Ford Bldg A27, Sydney, NSW 2006, Australia
[2] Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW, Australia
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2020年 / 02期
关键词
*Mucociliary Clearance; Administration; Inhalation; Cystic Fibrosis [physiopathology] [*therapy; Drug Administration Schedule; Saline Solution; Hypertonic; *administration; dosage; Sputum [metabolism; Female; Humans; Male; LUNG CLEARANCE INDEX; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE USE; HYALURONIC-ACID; ALTERNATE-DAY; PULMONARY EXACERBATIONS; MUCOCILIARY CLEARANCE; LESS-THAN-6; YEARS; MUCUS CLEARANCE;
D O I
10.1002/14651858.CD008816.pub4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Inhalation of hypertonic saline improves sputum rheology, accelerates mucociliary clearance and improves clinical outcomes of people with cystic fibrosis. This is an update of a previously published Cochrane Review. Objectives To determine whether the timing of hypertonic saline inhalation (in relation to airway clearance techniques or in relation to time of day) has an impact on its clinical efficacy in people with cystic fibrosis. Search methods We identified relevant randomised and quasi-randomised controlled trials from the Cochrane Cystic Fibrosis Trials Register, the Physiotherapy Evidence Database (PEDro), and international cystic fibrosis conference proceedings. Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register: 28 February 2019. Selection criteria Any trial of hypertonic saline in people with cystic fibrosis where timing of inhalation was the randomised element in the study protocol with either: inhalation up to six hours before airway clearance techniques compared to inhalation during airway clearance techniques compared to inhalation up to six hours after airway clearance techniques; or morning compared to evening inhalation with any definition provided by the author. Data collection and analysis Both authors independently assessed the trials identified by the search for potential inclusion in the review. The certainty of the evidence was assessed using GRADE. Main results The searches identified 104 trial reports which represented 51 trials, of which three cross-over trials (providing data on 77 participants) met our inclusion criteria. We present three comparisons: inhalation before versus during airway clearance techniques; inhalation before versus after airway clearance techniques; and inhalation during versus after airway clearance techniques. One trial (50 participants), given its three-arm design, was eligible for all three comparisons. No trials compared morning versus evening inhalation of hypertonic saline. The evidence from the three trials was judged to be of low quality downgraded for limitations (high risk of bias due to blinding) and indirectness (all participants are adults, and therefore not applicable to children). Intervention periods ranged from one treatment to three treatments in one day. There were no clinically important differences between the timing regimens of inhaling hypertonic saline before, during or after airway clearance techniques in the mean amount of improvement in lung function or symptom scores (77 participants), with the between-group comparisons being non-significant (low-certainty evidence). While there may be little or no difference in the rating of satisfaction when hypertonic saline was inhaled before versus during the airway clearance techniques (64 participants) (with the 95% confidence interval including the possibility of both a higher and lower rating of satisfaction), satisfaction may be lower on a 100-mm scale when inhaled after the airway clearance techniques compared to before: mean difference (MD) 20.38 mm (95% confidence interval (CI) 12.10 to 28.66) and when compared to during the techniques, MD 14.80 mm (95% CI 5.70 to 23.90). Perceived effectiveness showed similar results: little or no difference for inhalation before versus during airway clearance techniques (64 participants); may be lower when inhaled after the airway clearance techniques compared to before, MD 10.62 (95% CI 2.54 to 18.70); and also when compared to during the techniques, MD 15.60 (95% CI 7.55 to 23.65). There were no quality of life or adverse events reported in any of the trials. Authors' conclusions Timing of hypertonic saline inhalation makes little or no difference to lung function (low-certainty evidence). However, inhaling hypertonic saline before or during airway clearance techniques may maximise perceived efficacy and satisfaction. The long-term efficacy of hypertonic saline has only been established for twice-daily inhalations; however, if only one dose per day is tolerated, the time of day at which it is inhaled could be based on convenience or tolerability until evidence comparing these regimens is available. The identified trials were all of very short intervention periods, so longer-term research could be conducted to establish the effects arising from regular use, which would incorporate the influence of changes in adherence with long-term use, as well as generating data on any adverse effects that occur with long-term use.
引用
收藏
页数:44
相关论文
共 50 条
  • [21] Nebulised hypertonic saline solution for acute bronchiolitis in infants
    Zhang, Linjie
    Mendoza-Sassi, Raul A.
    Wainwright, Claire
    Klassen, Terry P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
  • [22] Contamination of hypertonic saline solutions in use by cystic fibrosis patients in Israel
    Peled, Orit
    Kalamaro, Vardit
    Kerem, Eitan
    Shoseyov, David
    Blau, Hannah
    Efrati, Ori
    Block, Colin
    JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (05) : 550 - 556
  • [23] Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
    Maiz Carro, Luis
    Lamas Ferreiro, Adelaida
    de Valbuena Maiz, Marta Ruiz
    Wagner Struwing, Carolin
    Gabilondo Alvarez, Gustavo
    Suarez Cortina, Lucrecia
    MEDICINA CLINICA, 2012, 138 (02): : 57 - 59
  • [24] Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study
    Pezzulo, Alejandro A.
    Stoltz, David A.
    Hornick, Douglas B.
    Durairaj, Lakshmi
    BMJ OPEN, 2012, 2 (02):
  • [25] Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review
    Maiz Carro, Luis
    Martinez-Garcia, Miguel A.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [26] Cured bronchi! Extending the use of nebulised hypertonic saline outside of cystic fibrosis?
    Martin, Clemence
    Regard, Lucile
    Burgel, Pierre-Regis
    EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (05)
  • [27] Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis
    Robinson, M
    Hemming, AL
    Regnis, JA
    Wong, AG
    Bailey, DL
    Bautovich, GJ
    King, M
    Bye, PTP
    THORAX, 1997, 52 (10) : 900 - 903
  • [28] Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis
    Trimble, Aaron T.
    Brown, A. Whitney
    Laube, Beth L.
    Lechtzin, Noah
    Zeman, Kirby L.
    Wu, Jihong
    Ceppe, Agathe
    Waltz, David
    Bennett, William D.
    Donaldson, Scott H.
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (05) : 650 - 656
  • [29] Inhaled hypertonic saline for 3-6-year-olds with cystic fibrosis
    Southern, Kevin W.
    Sinha, Ian P.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (09) : 730 - 732
  • [30] Hypertonic Saline for Inhalation: A Do It Yourself Recipe
    Amirav, Israel
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2017, 19 (12): : 784 - 785